Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01240980 | Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B) | PHASE1 | COMPLETED | 104 | — | — | Nov 1, 2010 | Jan 1, 2012 | Mar 15, 2012 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| BMS-903452 (0.1 mg) or Placebo - A1 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (0.6 mg) or Placebo - A2 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (3.0 mg) or Placebo - A3 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (10 mg) or Placebo - A4 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (30 mg) or Placebo - A5 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (60 mg) or Placebo - A6 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (120 mg) or Placebo - A7 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (0.6 mg) or Placebo - B1 | EXPERIMENTAL | (Subjects with type 2 Diabetes Mellitus) |
| BMS-903452 (10 mg) or Placebo - B2 | EXPERIMENTAL | (Subjects with type 2 Diabetes Mellitus) |
| BMS-903452 (120 mg) or Placebo - B3 | EXPERIMENTAL | (Subjects with type 2 Diabetes Mellitus) |
| BMS-903452 (10 mg) or Placebo - A11 | EXPERIMENTAL | (Healthy Subjects) |
| BMS-903452 (60 mg) or Placebo - A12 | EXPERIMENTAL | (Healthy Subjects) |
| Name | Type | Description |
|---|---|---|
| BMS-903452 | DRUG | Solution, Oral, 0.1 mg, once daily, 1 day |
| Placebo | DRUG | Solution, Oral, 0 mg, once daily, 1 day |
Inclusion Criteria: * Clinically healthy or Clinical diagnosis of Type 2 diabetes on a stable dose of metformin monotherapy Exclusion Criteria: * Type 1 Diabetes * History of significant heart disease * Prior bariatric surgery * Women of childbearing potential